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LETTER
Metformin improves survival in intensive care
unit patients, but why?
Niels P Riksen1,2*, Gerard A Rongen1,2 and Peter Pickkers3
See related research by Christiansen et al., http://ccforum.com/content/17/5/R192
We read with interest the study by Christiansen and col-
leagues [1] in the previous issue of Critical Care. In a large
cohort study, the authors report that among diabetic pa-
tients who are admitted to the ICU, the preadmission use
of metformin is associated with a lower mortality rate.
Here, we highlight that metformin limits ischemia-
reperfusion injury (IRI) and modulates inflammation by
increased adenosine receptor stimulation and propose
that these mechanisms contribute to the reported sur-
vival benefit.
In prospective studies in patients with diabetes, met-
formin use is associated with lower cardiovascular mor-
tality compared with alternative glucose-lowering agents,
suggesting a direct cardioprotective effect of metformin
[2]. In animal studies, metformin potently limits myocar-
dial infarct size [2]. This is caused, at least in part, by in-
creased formation of the endogenous nucleoside
adenosine [3]. Adenosine receptor stimulation increases
tolerance of various organs against IRI and potently
modulates inflammation [4]. Indeed, pharmacological
elevation of endogenous adenosine modulates the in-
flammatory response during experimental human endo-
toxemia [5].
In the study by Christiansen and colleagues, many pa-
tients were admitted to the ICU because of cardiovascu-
lar diseases or (non-)cardiac surgery. It is likely that in
these patients IRI contributes to organ dysfunction.
Therefore, we propose that the survival benefit of met-
formin is caused by limitation of IRI and inflammation
due to increased adenosine receptor signaling. Based on
this hypothesis, several randomized controlled trials are
currently being performed to investigate whether met-
formin reduces myocardial injury in patients with a
myocardial infarction and patients undergoing cardiac
surgery (NCT01438723 and NCT01217307). We await
with interest the results of these trials.
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Author’s response
Christian F Christiansen
Metformin and prognosis of critical illness: a
question of timing?
I would like to thank Riksen and colleagues for their re-
sponse to our article and for emphasizing that preven-
tion of IRI could contribute to our finding of a
decreased mortality among diabetic ICU patients with
preadmission metformin use [1]. The association we
found was present in, but not restricted to, the subgroup
of patients admitted after elective cardiothoracic surgery,
whereas there were no decreased mortality in patients
admitted after acute cardiothoracic surgery. Despite sta-
tistically imprecise estimates in the subgroups, it raises a
question about timing of metformin along the clinical
course of critical illness.
In sepsis, there is a proposed bi-phasic inflammatory
response, and any effect of potential anti-inflammatory
drugs, such as metformin, may be present only if admin-
istered before or during the early hyper-inflammatory
phase of infection whereas administration during the
later hypo-inflammatory phase may be detrimental [6,7].
Similarly, timing along the course of ischemia-
reperfusion may be crucial [3]. Studies of drug use in pa-
tients at high risk of critical illness (for example, patients
undergoing elective major surgery) are therefore import-
ant for our understanding of potential beneficial effects,
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as this exposure occurs before the inflammatory response
and the ischemia-reperfusion.
Therefore, I find it highly interesting that Riksen and col-
leagues are conducting trials with metformin administered
before coronary artery bypass grafting and after myocardial
infarction (NCT01438723 and NCT01217307). Although
the magnitude of the inflammatory response is different,
the studies will probably provide knowledge about the in-
fluence of timing of metformin administration in relation
to myocardial injury.
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